Product NDC: | 63323-193 |
Proprietary Name: | Irinotecan Hydrochloride |
Non Proprietary Name: | Irinotecan Hydrochloride |
Active Ingredient(s): | 20 mg/mL & nbsp; Irinotecan Hydrochloride |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-193 |
Labeler Name: | APP Pharmaceuticals, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA078188 |
Marketing Category: | ANDA |
Start Marketing Date: | 20090401 |
Package NDC: | 63323-193-02 |
Package Description: | 1 VIAL in 1 BOX (63323-193-02) > 2 mL in 1 VIAL |
NDC Code | 63323-193-02 |
Proprietary Name | Irinotecan Hydrochloride |
Package Description | 1 VIAL in 1 BOX (63323-193-02) > 2 mL in 1 VIAL |
Product NDC | 63323-193 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Irinotecan Hydrochloride |
Dosage Form Name | INJECTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20090401 |
Marketing Category Name | ANDA |
Labeler Name | APP Pharmaceuticals, LLC |
Substance Name | IRINOTECAN HYDROCHLORIDE |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Topoisomerase Inhibitor [EPC],Topoisomerase Inhibitors [MoA] |